An Italian compassionate-use program of dasabuvir in combination with ombitasvir/paritaprevir/ritonavir in patiens with HIV/HCV coinfection

Trial Profile

An Italian compassionate-use program of dasabuvir in combination with ombitasvir/paritaprevir/ritonavir in patiens with HIV/HCV coinfection

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C; HIV infections
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 New trial record
    • 09 Feb 2017 Primary endpoint (Percentage of patients achieving SVR12 (HCV RNA <25 IU/mL [lower limit of quantitation, LLOQ])) has been met, according to the article published in the Clinical Infectious Diseases.
    • 09 Feb 2017 Results published in the Clinical Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top